Proteins deacetylation by Histone deacetylase 6 (HDAC6) has been shown in various human chronic diseases like neurodegenerative diseases and cancer, and hence is an important therapeutic target. Since, the existing inhibitors have hydroxamate group, and are not HDAC6-selective, therefore, this study has designed to investigate non-hydroxamate HDAC6 inhibitors. Ligand-based pharmacophore was generated from 26 training set compounds of HDAC6 inhibitors. The statistical parameters of pharmacophore (Hypo1) included lowest total cost of 115.63, highest cost di®erence of 135.00, lowest RMSD of 0.70 and the highest correlation of 0.98. The pharmacophore was validated by Fischer's Randomization and Test Set validation, and used as screening tool for chemical databases. The screened compounds were¯ltered by¯t value (> 10:00), estimated Inhibitory Concentration (IC 50 ) (< 0:459), Lipinski's Rule of Five and Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET ) Descriptors to identify drug-like compounds. Furthermore, the drug-like compounds were docked into the active site of HDAC6. The best docked compounds were selected having gold¯tness score > 66:46 and chemscore < À28:31, and hydrogen bond interaction with catalytic active residues. Finally, three inhibitors having sulfamoyl group were selected by Molecular Dynamic (MD) simulation, which showed stable root mean square deviation (RMSD) (1.6-1.9 Å), lowest || Corresponding authors.
Introduction
Histone acetyltransferases (HATs) and histone deacetylases (HDACs) are conserved classes of enzymes that primarily catalyze epigenetic acetylation and deacetylation of lysine residues, respectively. 1, 2 These enzymes are key players of cellular signaling network and regulate several biological processes including gene expression, epigenetic modulation, cell di®erentiation and cell death, cardiac function, in°ammation, protein proteostasis, and neuroplasticity. [3] [4] [5] [6] [7] [8] [9] [10] To date, 18 di®erent HDACs have been identi¯ed and characterized as 4 di®erent classes, based on their mutual homology of catalytic domains (CDs). The substantial targets of HDACs are both histones and non-histone proteins including tubulins, heat shock protein 90 (HSP90), cortactin, etc. [11] [12] [13] [14] Histone deacetylase 6 (HDAC6) has been characterized as class IIb HDAC with subcellular localization in cytosol. HDAC6 modulates diverse functional repertoire via deacetylation and is unique in all HDACs due to the presence of two CDs (CDI and CDII), sandwiched by N-terminus and an ubiquitin-binding motif (the Binding of Ubiquitin Zinc (BUZ)¯nger) as its C-terminus. [15] [16] [17] In parallel with chromatin remodeling and gene transcription, HDAC6 has been investigated to target several non-histone proteins to modulate vital cellular processes including cell division, aggresome formation, intracellular tra±cking, misfolded protein aggregation, and cell protection. For instance, the deacetylation of -tubulin by HDAC6 has crucial impact on microtubule network, eventually leads to their stability and regulates cell migration and cell-cell interactions. [18] [19] [20] [21] [22] [23] [24] [25] HDAC6 is recognized as a potential therapeutic target in many devastating diseases like disorders of central nervous system such as Alzheimer's, Parkinson's, and Huntington's diseases as well as in°ammatory breast cancer, myeloma, and lymphoid malignancies. 1, [26] [27] [28] [29] [30] Recently, HDAC6 is considered an ideal therapeutic target due to its substrates diversity and fueling tumorigenesis which includes histone proteins, HSP90, tubulin, cortactin, and peroxiredoxins. 19, 21, 31, 32 To date, a number of HDACs inhibitors have been investigated. Most common HDAC6 inhibitors are panobinostat (LBH-589) and vorinostat (suberovlanilide hydroxamic acid (SAHA)), however, they are often administrated against several HDACs. 33 Several other HDACs inhibitors including tubacin and tubastatin A have also been administrated as HDAC6-speci¯c antagonists. However, these inhibitors have their own limitations and challenges. For instance, tubacin was developed in a chemical genetic screening which could potentially inhibit cell motility. Due to unfavorable pharmacokinetic pro¯les like high lipophilicity and expensive synthesis, tubacin is regarded as a useful research tool rather than a routine drug. 21, 34, 35 Ricolinostat is a potent HDAC6 inhibitor while its propensity towards class I HDACs is 10-12 fold greater than HDAC6. In clinical phase I/II, ricolinostat is administrated in combination with dexamethasone and its e±ciency may further be cooperated by either lenalidomide or borezomib against multiple myeloma. 36 Nexturastat A is another highly active HDAC6 inhibitor with antiproliferative in°uence on B16 melanoma cells but its high selectivity towards HDAC1 (> 600 fold) has hampered its compatibility to use as HDAC6-speci¯c antagonist. 37 Apart from that, tubastatin A (Inhibitory Concentration (IC 50 ) 15 nM/L for HDAC6) is a carbazole hydroxamic acid which has antihepatitis C activity and bypassing the neuronal toxicity of unselective HDACs inhibitors. 21, 35 Since, all these HDACs inhibitors contain hydroxamate group as their mechanism making moiety, therefore, we hypothesized that inhibitors other than hydroxamate group might enhance their speci¯city towards HDAC6. To test this hypothesis, we have attempted to identify non-hydroxamate inhibitors against HDAC6.
Selective inhibition of HDAC6 has emerged as a promising platform against different types of cancers, Rheumatoid arthritis, Alzheimer's disease, Parkinson's disease, and Huntington's disease. 26, 34, 38, 39 The development of HDAC6 selective inhibitors is prompted by their endeavors as anticancer agents like etoposide, doxorubicin, and vorinostat to drive transformed cell death rather than normal cells but their optimization are still underway. 25 In an attempt to design nonhydroxamate sca®olds for HDAC6 inhibition, we employed in silico screening of chemical databases (DBs) via three-dimensional Quantitative structure Activity Relationship (3D-QSAR) pharmacophore modeling. The pharmacophore-screened compounds were further¯ltered by drug-like properties including Lipinski's Rule of Five and Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET ) Assessment test. The drug-like hits were evaluated by molecular docking to eliminate false positive hit compounds. The binding mode and binding conformation of the selected hits was a±rmed by molecular dynamic (MD) simulation. Finally, three potential candidate molecules were identi¯ed as promising virtual leads for the development of non-hydroxamate HDAC6 inhibitors.
Material and Methods

Dataset preparation
In this study, a total of 890 HDAC6 inhibitors were collected from binding DB 62 and di®erent literature surveys. 21, 33, 35, 37, 40, 41 The compounds were classi¯ed by their IC 50 values, drug-like properties, and a dataset of 74 compounds was selected. The dataset was divided into training set (26 compounds) and test set (48 compounds) . The training and test set compounds were classi¯ed into three groups based on their IC 50 values: highly active (IC 50 100 nM/L), moderately active (100 IC 50 < 10; 000 nM/L) and inactive (IC 50 ! 10; 000 nM/L). The two-dimensional (2D) structure of compounds were drawn by ChemSketch (ACD Inc., Toronto, Canada) and converted into their respective 3D structures using Discovery Studio v4.5 (hereafter, DS).
Development of 3D-QSAR pharmacophore model
The chemical features of training set compounds were explored by Feature Mapping Protocol implanted in DS. The most important features like hydrogen bond acceptor (HBA), hydrogen bond donor (HBD), ring aromatic (RA), hydrophobic aromatic (HA), and hydrophobic (HYP) were considered during hypotheses generation. To generate hypotheses for pharmacophore model development, 3D-QSAR Pharmacophore Generation Protocol was executed with BEST algorithm, implanted in DS. [42] [43] [44] The uncertainty range was relaxed to 3 and the energy threshold value was optimized to 20 kcal/mol. The minimum and maximum number of features in all the hypotheses were set to 1 and 5, respectively. Other parameters were used as default values including minimum feature points (4), minimum subset points (4), weight variation (0.302), variable weights (false), and variable tolerances (false). Ten quantitative hypotheses were generated based on their respective statistical parameters like cost values (null and¯xed costs), correlation coe±cient (r), root mean square deviation (RMSD), and¯t values. The cost values were evaluated as per Debnath's approach. 45 
Validation of pharmacophore model
Based on statistical parameters, a given hypothesis (e.g. Hypo1) is tested for its functional reliability. The generated model was validated by Fischer's Randomization and Test Set validation. Fischer's randomization calculates the signi¯cance of hypothesis by the equation: S ¼ ½1 À ð1 þ XÞ=Y Â 100, where X denotes the total number of hypotheses, while Y is the total number of HypoGen runs. This method is prompted by its ability to evaluate the correlation between the biological activities and the chemical structures. Fischer's randomization was used to substantiate generation path of the selected hypothesis. The con¯dence level was restrained to 95% and 19 random spreadsheets were produced in DS. 46 Test set validation evaluates the capability of Hypo1 to predict and classify the compounds based on their activity range. Herein, the test set was comprised of 48 chemically diverse structures with inclusive inhibitory values as compared to training set compounds. The Hypo1-based pharmacophore was employed to predict the activity scale of test set molecules. The predicted and experimental activity values were plotted to con¯rm their mutual correlation.
Virtual screening of chemical DBs
Pharmacophore-based virtual screening identi¯es the best-¯tted compounds onto pharmacophore and their appropriate mapping to all the existed features in the corresponding pharmacophore. Four chemical DBs including Asinex, NCI, Maybridge, and Chembridge were screened by validated pharmacophore model to identify novel sca®olds as potential HDAC6 domain-selective inhibitors. The Ligand Pharmacophore Mapping protocol with BEST and FLEXIBLE parameters was employed in the screening process. The compounds overlaid onto all the features of pharmacophore model were selected for further analysis.
Estimation of drug-like properties
The retrieved compounds from all the chemical DBs were subjected to Lipinski's Rule of Five to estimate drug-like properties. This rule recommends that a drug would be e±cient to absorb into biological membranes if the number of HBA is less than 10, the number of HBD is less than 5, LogP (compound's lipophilicity) is less than 5 and compound's molecular weight is less than 500 g/mol. 47 The compounds that have passed the Lipinski's Rule of Five were subjected to ADMET Descriptors protocol in DS to calculate ADMET properties. According to this protocol, the compounds ful¯lling the criteria for low blood-brain barrier (BBB) (estimated value 3), optimum solubility (estimated value 3), well absorption rate (calculated value 0), and negative CYP2D6 binding, and non-hepatotoxic e®ects were¯ltered.
Molecular docking simulation
To predict the binding mode of screened compounds in HDAC6 active site, molecular docking was performed using Genetic Optimization of Ligand Docking (GOLD) package (v5.2.2). Since, protein 3D structure is an essential input¯le for proteinligand docking, we have taken the X-ray structure of human HDAC6 domain II from Protein Data Bank (PDB ID: 5EDU) with resolution 2.79 Å and bound ligands trichostatin A and Zn 2þ . 48 As mentioned earlier, the domain II of HDAC6 is essential for enzymatic activity and it is articulated that the inhibition of this domain may halt the HDAC6 deacetylation potential. 40, 41, 59 The training set compounds as well as drug-like hit compounds were subjected to molecular docking calculations. Prior to docking, the protonation state of only three catalytic histidine residues (His610, His611, His651) were de¯ned as NE2H, as recommended, 49 while others were assigned to ND1H state. The binding site of the HDAC6 was de¯ned by executing De¯ne and Edit Binding Site protocol implemented in DS. Gold¯tness score was used as the default scoring function to evaluate the binding a±nity of hit compounds towards the catalytic residues of HDAC6. In parallel, Chemscore.DG was executed to evaluate rescoring function. The highest gold¯tness score and the lowest chemscore.DG values for highly active compound in training set (reference compound) were taken as cut-o® values to select the best-¯tted hit compounds.
MD simulation
MD simulation is a state-of-the-art approach to evaluate the stability of receptorligand complex. Four di®erent systems, three hits and a reference compound in complex with HDAC6 were subjected to 20-ns MD simulation using GROningen MAchine for Chemical Simulations (GROMACS) package (v5.1.7) with Amber03 force¯eld. 50 During protein topology production, all the histidine residues were protonated at ND1H position except His610, His611, and His651, where they were assigned NE2H state. 49 Topology and coordinates for each compound were generated by AnteChamber Python Parser interfacE (ACPYPE). 51 Each system was inserted into an octahedral box, solvated with TIP3P water model, and neutralized by the addition of Na þ as counter ions. Energy minimization was achieved by 1000 minimization steps with steepest descent algorithm and maximum force lower than 10 kJ/mol to remove all bad contacts in initial structure. The energy minimized system was subsequently subjected to equilibrations with 100 ps Number of atoms, Volume, and Temperature (NVT) and 100 ps Number of atoms, Pressure, and Temperature (NPT) ensembles. The constant temperature (300 K) and pressure (1 bar) were maintained by V-rescale thermostat and Parrinello-Rahman barostat, respectively. 52, 53 During equilibrations, the protein backbone was restrained, while the rest of the system was allowed to move. The geometry of water molecules and hydrogen bonds were constrained using SETTLE and LINear Constraint Solver (LINCS ) algorithms, respectively. 54, 55 Periodic Boundary Condition (PBC) was applied to avoid edge in°uences. In order to calculate long-range electrostatic interactions, Particle Mesh Ewald (PME) algorithm was used. 56 Each simulation was executed for 20 ns and the coordinates data were saved at every 2 ps. Simulations results were analyzed by Visual Molecular Dynamics (VMD) 57 and DS tools.
Results and Discussion
Generation of 3D-QSAR pharmacophore model
All the training set compounds (26 molecules) were divided into three groups based on their IC 50 values, highly active (IC 50 100 nM/L), moderately active (100 nM/L IC 50 < 10; 000 nM/L), and inactive (IC 50 ! 10; 000 nM/L) (Fig. 1) . The 3D-QSAR pharmacophore models were generated from the training set compounds using HypoGen algorithm. Among the 10 generated hypotheses, Hypo1 was considered as the best pharmacophore model based on statistical parameters (Table 1) . Hypo1 showed lowest total cost of 115.63, highest cost di®erence of 135.00, lowest RMSD value of 0.70, and highest correlation value of 0.98 (Table 1) . Hypo1 is comprised of four chemical features including 1 HBA, 1 HBD, 1 RA, and 1 HYP. The 3D spatial orientation and inter-features distance constraints of the model are depicted in Fig. 2 .
To con¯rm the predictive capability of the model, the inhibitory activity of all the training set compounds was estimated using Hypo1. The results indicated that Hypo1 successfully classi¯ed all the training set compounds in an order corresponded to their activity range except for two active and two moderate active compounds, where they were estimated as moderate active and inactive, respectively (Table 2 ).
Hypo1 mapping onto active and inactive compounds showed that the highly active compound aligned all features of the pharmacophore (Fig. 3(a) ). Conversely, the inactive compound mapped HBA and RA features of the modeled pharmacophore ( Fig. 3(b) ). 
Validation of the generated model
Parmacophore validation was performed by Fischer's Randomization and Test Set method to evaluate the quality of the model. At 95% con¯dence level, Hypo1 had the lowest total cost value among all the 19 spreadsheets produced randomly (Fig. 4) . The estimation of lowest total cost value of the resultant pharmacophore authenticated its statistical signi¯cance. Test set validation was also conducted using a test set, comprised of 48 structurally diverse compounds. The model was able to sort out test set according to their activity ranges. The regression analysis of test set compounds showed a signi¯cant coincidence with correlation coe±cient (r ¼ 0:94) between the predicted scale and experimental inhibitory scale based on Hypo1 (Fig. 5, Table S1 ). Pharmacophore validation advocated that Hypo1 can be used as 3D structural query to screen chemical DBs. 
Virtual screening and identi¯cation of drug-like compounds
Virtual screening is an alternative technique to high-throughput approach in drug discovery process. 
Identi¯cation of candidate compounds from molecular docking studies
To eliminate false positive compounds among the predicted hits,¯ltered compounds (107 hits) and the training set compounds were docked into the active site of HDAC6. The coordinates for HDAC6 docking site were de¯ned from the reported catalytic residues His610, His611, Asp649, His 651, Asp742, and Tyr782 of human HDAC6. 40, 41, 59, 48 Docking results were evaluated by gold¯tness score (default scoring function), chemscore.DG (rescoring function), and interactions with catalytic active residues. The highly active compound of the training set (IC 50 ¼ 0:459 nM/L) was taken as reference compound. Gold¯tness score and chemscore.DG for the reference compound were 66.46 and À28.31, respectively (Table 3) .
Based on scoring criteria, hit compounds having gold¯tness score ð> 66:46Þ and chemscore.DG ð< À28:31Þ were selected. The gold¯tness score and chemscore.DG values of the hit compounds were in the range from 70.88 to 73.90 and from À48.47 to À36.78, respectively ( Table 3 ). The selected candidate hit compounds also satis¯ed molecular interactions with catalytic residues of HDAC6. Molecular overlay of hit compounds onto pharmacophore model revealed that the¯nal three hits were well matched all features of the pharmacophore model (Fig. S1 ).
Binding mode analysis of the¯nal hit compounds
MD simulation is performed to evaluate the binding stability of receptor-ligand complex and to re¯ne the binding mode of the ligand. In this study, four di®erent systems, a reference compound and three hits in complex with HDAC6 were subjected to 20-ns MD simulation. MD simulation resulted in stable RMSD which was ranged from 1.6 to 2.0 Å during the entire simulation period and well converged in all the four systems (Fig. 6) .
The average RMSD value for individual system was 1.7, 1.6, 1.6, and 1.9 Å for the reference compound, Hit1, Hit2, and Hit3, respectively. The calculation of potential energy showed that the reference compound as well as the entire hit compounds had lowest potential energy and no abnormal behavior observed during the entire simulation period (Fig. S2) .
The representative structure for each complex system was taken from the last 5-ns trajectories to evaluate receptor-ligand interaction pattern. When all the representative structures were superimposed, it was observed that the binding orientation of all the hit compounds as well as the reference compound occupied the same catalytic pocket of HDAC6 (Fig. 7) . Furthermore, it was revealed that all the hits showed stronger molecular interactions in terms of both hydrophobic and hydrogen bond formation (Table 4) . Since, HDAC6 has shallow and wide-rimmed substrate-binding site, therefore, the hit compounds could not occupy the entire catalytic pocket of HDAC6 due to their narrow cap and linker regions (Fig. 7) . Our comparative analysis speculated that chemical incorporation of bulkier groups into the newly identi¯ed hits may augment their stability and e®ectiveness.
Selective inhibition of HDAC6 was recently achieved very rarely while domainspeci¯c inhibition is still unrevealed. 40, 58 The domain II (CDII) of HDAC6 is the preferred ligand binding site and is comprised of His610, His611, Phe620, Asp649, His651, Phe680, Asp742, and Tyr782. 40, 41, 59, 60 All these important residues were strongly involved in molecular interactions with hit compounds (Fig. 8) . Our study showed that all the four compounds occupied the same binding site and sandwiched between the Phe620 and Phe680. 41 The reference compound as well as all the hit compounds formed stable hydrogen bond interactions with important catalytic residues such as His610, His611, Asp649, His651, Asp742, and Tyr782 (Table 4 ). The reference compound formed hydrogen bonds with His611, Asp649, and Gly780 of HDAC6 (Fig. 8(a) ). Our data observed high frequency of long-range electrostatic interactions driven by nitrogen atom of hydroxamate group in reference compound. The same pattern of electrostatic interactions was established by the sulfur atom of sulfamoyl group in all the newly identi¯ed hit molecules. This observation also supports our predicted hit compounds as fundamental platforms for the development of novel inhibitors against the HDAC6. In addition, -T -shaped interaction was observed between the imidazole group of His611 and the reference compound. The reference compound also established a number of HYP and Van der Waals interactions with the catalytic residues of HDAC6 (Table 4) . Our results showed that Hit1 formed hydrogen bonds with Asp649, His651, and Tyr782 ( Fig. 8(b) ). The corresponding residues atom and hydrogen bond length are shown in Table 4 . The sulfamoyl group of Hit1 also showed salt bridges with catalytic active residues including Asp649 and Asp742. Apart from that, Hit1 showed -stacked interaction with His611 and -T -shaped interaction with His651. Residues of HDAC6 which established hydrophobic and Van der Waals interactions are depicted in Table 4 .
The newly identi¯ed Hit2 molecule formed hydrogen bonds with Leu749 and Tyr782 (Fig. 8(c) ). The Hit2 molecule showed high frequency of salt bridge interactions including highly active residues like Asp649, His651, and Asp742. Moreover, Hit2 also established hydrophobic interactions with the catalytic residues of HDAC6 (Table 4) . Furthermore, Hit3 also formed stable hydrogen bonds with His610 and His611 ( Fig. 8(d) ). The non-bonded interaction of Hit3 was comprised ofstacking between Hit3 and Phe620, -sulphur interactions with Cys621 and Met682, and other Van der Waals interactions (Table 4) .
In our analysis, it was observed that sulfamoyl moiety in all hit compounds was essential for hydrogen bond formation with the catalytic residues of HDAC6. Furthermore, it was articulated that sulfur atom of the sulfamoyl moiety played a crucial role in hydrophobic inhibition of HDAC6. Nonetheless, the previously identi¯ed inhibitors of HDAC6 harbor hydroxamate group as their distinguished feature. 33, 40, 41, 59, 60 Our newly identi¯ed candidate hits has sulfamoyl group as their mechanism-making avenue. The same binding pattern was found in hydroxamate group of reference compound (Fig. 8) . In addition, the presence of terminal hydrogen of NH group of sulfamoyl moiety in the entire candidate hits facilitated additional hydrogen bonding with catalytic active residues of HDAC6 (Fig. 8, Table 4) .
Moreover, the calculation of the total number of intermolecular hydrogen bonds between the protein and the hit compounds showed that the reference and Hit1 showed almost the same average number of hydrogen bonding. Conversely, Hit2 and Hit3 showed slightly less number of hydrogen bonds than the reference compound (Fig. 9) .
Our rational analysis suggested that linker and cap regions of the ligand play important role in the orientation of hydroxamate and/or sulfamoyl moiety of the concerned inhibitor in the catalytic pocket of HDAC6. Since, the catalytic pocket of HDAC6 is characterized by a deep tunnel and a shallow-rimmed surface, so the desired inhibitor is suggested to have narrow linker region and bulky cap region. Therefore, we argued that the sulfamoyl-constituted compounds may be exploited as fundamental platforms to develop selective inhibitors of HDAC6.
Furthermore, the PubChem search tool 63 con¯rmed that till the date, the newly identi¯ed hits were not investigated against HDAC6 inhibition. Therefore, we suggest that these three candidate hits might be used as starting sca®olds for the development of novel chemotherapeutics against HDAC6-associated pathogenesis. The 2D structures and International Union of Pure and Applied Chemistry (IUPAC) names of the¯nal hits are depicted in Fig. 10 .
HDAC6 speci¯city assessment
Since, we speculate the proposed speci¯city of newly identi¯ed inhibitors towards HDAC6, therefore, a comparative analysis was carried out. Herein, the crystal structure of HDAC8 (PDB ID: 1T64) was taken as the o®-target protein because both the proteins (HDAC6 and HDAC8) share very similar active site topology and conserved catalytic residues. The newly identi¯ed inhibitors were docked in the same catalytic site of HDAC8 where the original co-crystal inhibitor was bound while utilizing the same protocol as for HDAC6 docking. The docking score analysis suggested that Hit1 had gold¯tness score of 68.38 and could occupy the same catalytic site as the co-crystal inhibitor (Table S2 ). The godl¯tness scores for Hit2 and Hit3 were observed as 67.38 and 73.89, respectively. In contrast to high gold¯tness score, all the hit molecules showed signi¯cantly low chemscore (Table S2) . Since, the hits showed relatively high gold¯tness scores but signi¯cantly low chemscore against the presumed o®-target (HDAC8), therefore, we asked whether the newly identi¯ed inhibitors interacted the catalytic residues of HDAC8 or not? The catalytic site of HDAC8 is comprised of His142, His143, Asp178, His180, and Tyr306. 61 The structural analysis of docked hits in HDAC8 showed that all the proposed inhibitors of HDAC6 could not bind the catalytic residues of HDAC8 despite their relatively high docking scores (Fig. 11) .
The docking analysis suggested that Hit1 could not form hydrogen bond(s) with any of the catalytic residues of HDAC8 ( Fig. 11(a) ), whereby hydrogen bond formation with catalytic residues is essential for HDAC8 inhibition. 61 In contrast, nevertheless, Hit1 showed hydrophobic and Van der Waals interactions with HDAC8, but the sulfamoyl group of Hit1 was absolutely deprived of interactions with catalytic residues (Fig. 11(a) ).
Our analysis observed that Hit2 formed hydrogen bonds with Phe208 and Tyr306 of HDAC8, but the other catalytic residues could not establish stable interactions with essential catalytic residues (Fig. 11(b) ). Therefore, it is speculated that a single hydrogen bond formation by non-sulfamoyl group with Try306 of HDAC8 will not potentiate its inhibition. Apart from that, the sulfamoyl group of Hit2 formed a hydrogen bond with Phe208 of HDAC8 which we cannot trust worthy for HDAC8 inhibition due to its passive participation in catalytic mechanism. Moreover, the number of hydrophobic interaction of Hit2 was not high enough to support HDAC8 inhibition ( Fig. 11(b) ). Finally, the binding analysis of Hit3 suggested that the sulfamoyl group formed a hydrogen bond with Phe208 which is not su±cient for HDAC8 inhibition (Fig. 11(c) ). Furthermore, it was observed that Hit3 followed the same pattern as Hit2 to establish hydrophobic interactions. Therefore, we suggest that Hit3 may not be able to inhibit HDAC8. The importance of hydrogen bond formation by catalytic histidine residue(s) has already been explained in MD simulation section. Based on these results, we proclaim that these newly identi¯ed inhibitors will not be able to inhibit HDAC8 despite their relatively high docking scores. Moreover, the orientation of each hit molecule was also traced in the active site of HDAC8. It was observed that the mechanism-making moiety of each hit molecule (sulfamoyl group) was laying outside the catalytic site and could not reach the essential catalytic residues of HDAC8 (Fig. S3 ). Our study proclaims that the sulfamoyl group must occupy the catalytic pocket to inhibit the target protein. All these evidences suggest that the hit molecules may be HDAC6 speci¯c.
Conclusion
Protein acetylation and deacetylation are considered as the major contributors of di®erent cellular processes. Irregularity of protein deacetylation causes several diseases including neurological disorders and di®erent types of cancer. HDAC6 is one of such enzymes which can promote protein deacetylation by the catalytic removal of "-amino of conserved lysine residues in di®erent substrates. To overcome the deleterious e®ects caused by HDAC6-mediated deacetylation, the current study was designed to identify non-hydroxamate sca®olds against HDAC6. Herein, a pharmacophore model was generated and validated using Fisher's Randomization and Test Set methods. The pharmacophore model was used to screen four chemical DBs including NCI, Maybridge, Chembridge, and Asinex. The pharmacophore-retrieved compounds were¯ltered by Lipinski's Rule of Five and ADMET properties to identify drug-like compounds. The 3D structure of human HDAC6 was taken from PDB (ID: 5EDU) and the drug-like hit compounds (107 hits) were docked into its active site by GOLD software. The best hit compounds were selected on the basis of gold¯tness score, chemscore.DG, and hydrogen bonds with catalytic active residues of HDAC6. The¯nal three hit compounds were subjected to 20-ns MD simulation to investigate their binding modes. The MD simulation results showed that the hit compounds formed several interactions including hydrogen bonds, -stacking, -cation, -sulphur and hydrophobic interactions with the active site residues of HDAC6. Moreover, the proposed speci¯city of the newly identi¯ed hits was also assessed against HDAC8 by docking analysis. Hence, we suggest the¯nal hits as promising platforms for the development of novel HDAC6 inhibitors.
